墨西哥总医院接受双膦酸盐治疗的肿瘤患者颌骨骨坏死患病率及口腔特征
Prevalence of osteonecrosis of the jaw and oral characteristics of oncologic patients treated with bisphosphonates at the General Hospital of Mexico.
作者信息
Cuevas-González María Verónica, Díaz-Aguirre Celia Minerva, Echevarría-Y-Pérez Enrique, Cuevas-González Juan Carlos
机构信息
Department of Maxillofacial Prosthetics, General Hospital of México, Mexico City, Mexico.
Department of Stomatology, Institute of Biomedical Sciences, Autonomous University of Ciudad Juárez, Ciudad Juárez, Mexico.
出版信息
J Korean Assoc Oral Maxillofac Surg. 2016 Dec;42(6):365-369. doi: 10.5125/jkaoms.2016.42.6.365. Epub 2016 Dec 27.
OBJECTIVES
To determine the prevalence and oral characteristics of cancer patients treated with bisphosphonates in the oncology and maxillofacial prosthesis departments of the General Hospital of Mexico between 2011 and 2013.
MATERIALS AND METHODS
This cross-sectional study included patients who received prior treatment with bisphosphonates; an intraoral examination was performed by 2 standardized examiners.
RESULTS
The prevalence of bisphosphonate-related necrosis in 75 patients was 2.6%; the most common malignancy was breast cancer (84.0%), followed by prostate cancer (16.0%). Exostosis was present in 9.3% of patients and the mean Decayed, Missing, Filled Teeth index was 4.64; 44.0% of the study group had a Community Periodontal Index value between 2 and 2.9 (mean, 0.60).
CONCLUSION
A detailed intraoral assessment must be performed before initiating treatment with bisphosphonates to identify risk factors for osteonecrosis.
目的
确定2011年至2013年期间在墨西哥总医院肿瘤学和颌面修复科接受双膦酸盐治疗的癌症患者的患病率及口腔特征。
材料与方法
这项横断面研究纳入了之前接受过双膦酸盐治疗的患者；由2名标准化检查人员进行口腔检查。
结果
75例患者中双膦酸盐相关骨坏死的患病率为2.6%；最常见的恶性肿瘤是乳腺癌（84.0%），其次是前列腺癌（16.0%）。9.3%的患者存在外生骨疣，龋失补牙指数平均为4.64；44.0%的研究组患者社区牙周指数值在2至2.9之间（平均为0.60）。
结论
在开始双膦酸盐治疗前必须进行详细的口腔评估，以确定骨坏死的危险因素。
Zotero 插件